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Abstract 
Male breast cancer (MBC) is rare, with the peak age of onset at 71 years. BRCA2 mutations are more frequent than BRCA1 with 20% of 
cases giving a family history. Risk factors for MBC are poorly understood and include working in high-ambient temperatures and exhaust 
fume exposure. MBC is associated with hyperoestrogenic states found in liver disease, Klinefelter's syndrome, gonadal dysfunction or 
obesity. Most information on treatment of MBC is derived from large randomized trials carried out in female patients. The small numbers 
of MBC seen in any unit annually has precluded significant trials being carried out. 
Diagnosis and treatment of MBC is similar to that of female patients, but men tend to be treated with mastectomy rather than breast-
conserving surgery. The mainstay of adjuvant therapy or palliative treatment for advanced disease is endocrine, mostly tamoxifen. 
Prognosis of male patients is equal to that of stage-matched women, but men tend to fare worse because of delay in presentation, 
leading to a large proportion of patients presenting with stage III or IV disease. Increased input is needed for psychological support for 
male breast cancer patients. Specific therapeutic questions about MBC need international trials to obtain meaningful answers. 
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Background 
Male breast cancer is a relatively rare disease in the western 
world accounting for <1% of all breast cancers. The causes are 
poorly understood and most studies are small and 
underpowered so that treatment decisions derive from large 
trials in post-menopausal women. Although the outlook for men 
is the same as stage-matched women, overall the prognosis is 
worse because of delayed presentation—on average 6–10 
months from symptom onset to diagnosis [1], with only slight 
improvement in survival over the last 25 years [2]. 
The incidence of MBC in Northwest Europe and North America 
is approximately 1/100,000 but is increasing [3]. Disease 
frequency is higher among Jewish men at 2.3/100,000 and in 
countries with a high incidence of parasitic liver disease such as 
Egypt and Zambia [4,5]. In Japan, where the incidence of 




Although several risk factors for MBC have been identified, 
most men with the disease have none other than increasing age 
(average age of diagnosis is 71 years, approximately ten years 
older than in women [7]. Most risk factors relate to either 
testicular malfunction or an increase in oestrogen (Table 1). 
Genetic 
As in women, risk of breast cancer increases with number of 
first degree relatives with the disease particularly with early age 
at diagnosis. In 15–20% of MBC cases there is a positive family 
history [8]. More rarely, men are found to have BRCA1 and 
BRCA2 mutations, usually the latter. A male BRCA2 carrier has 
a 6% lifetime risk of developing the disease, compared with 
0.1% in the normal population [9]. MBC has been reported in 
those with Cowden syndrome [10], but not in men with Li 
Fraumeni syndrome. Individuals with Klinefelter's syndrome 
(XXY) have a 20 to 50-fold increased risk of breast cancer and 
a mortality rate similar to that of females [11,12]. 
Occupation 
Men working in hot environments such as blast furnaces, steel 
works and rolling mills have increased risk of MBC [8]. 
Associations have also been found with occupations involving 
working with soap, perfume, petrol or exhaust fumes [13,14]. 
The responsible carcinogens are probably polycyclic aromatic 
hydrocarbons (PAH), present in tobacco smoke and exhaust 
emissions. Exposure to electromagnetic fields has been 
postulated as a risk factor but evidence for this is limited and 
negative [15]. 
Radiation exposure 
Radiation exposure increases risk of breast cancer for both 
women and men [16]; small numbers of chest X-rays do not, but 
prolonged exposure to radiographs or radiotherapy may be 
harmful [17]. Radiotherapy has been used in high doses to treat 
gynaecomastia and a sevenfold increase in the relative risk of 
breast cancer has been reported in these patients [18]. Some 
institutions still use low-dose radiotherapy for this condition and 
the long-term effects of this remain to be seen [19]. Among the 
45,880 survivors of an atomic bomb, MBC risk increased up to 
eightfold, depending on the extent of exposure [20]. 
Endocrine factors 
MBC risk is affected by oestrogen/testosterone balance with 
increased rates in men taking exogenous oestrogens, such as 
prostate cancer patients and transsexuals [21,22]. Testicular 
dysfunction as a result of congenital inguinal hernia, infertility, 
testicular injury, orchidectomy and mumps orchitis at age 
increases risk of MBC by up to twelve-fold [23]. 
Obesity commonly causes hyperestrogenism in men and some 
studies suggest that it can double the risk of MBC [24,25]. Liver 
disease such as cirrhosis also causes hyperestrogenism 
associated with an increased risk of MBC [26]. A European 
multi-centre study with 74 cases and 1432 population controls 
reported a significant relationship between alcohol consumption 
and risk of MBC [27]: the odds ratio for alcohol intake >90 g/d 
was 5.89 (CI 2.21–15.69). The risk of MBC rose by 16% for 
every 10 g of daily alcohol intake. Male breast cancer has been 
described in patients with hyperprolactinaemia due to pituitary 
adenomas [28]. There is however no proven link between 
gynaecomastia and male breast cancer [29]. 
 
Presentation 
As in female patients, most males (75%) complain of a painless 
mass [30]. Other presenting features include nipple retraction, 
nipple discharge, ulceration and pain [31]. Differential diagnosis 









Table 1: Risk factors for male breast cancer 
 
Table 2: TNM stage at presentation for male breast cancer 
 
 
includes gynaecomastia, abscess, metastatic disease or rarely, 
sarcoma. Because the male breast is rudimentary and most 
tumours are central, nipple involvement is seen in up to 50% of 
cases at presentation [32]. Despite some increased awareness 
of MBC, there is still a delay of 6–10 months from onset of 
symptoms to diagnosis [2]. Of the patients, >40% of men 
present with stage III or IV disease (Table 2) [29,30,33,34].   
 
Diagnosis 
As with symptomatic female patients, the diagnosis is made by 
triple assessment, with both mammography and ultrasound 
scanning having high sensitivity and specificity for male patients 
[35]. Fine needle aspiration cytology and core biopsies may be 
used, but core biopsy is preferred because it enables a 
definitives diagnosis to be made in the majority of cases. MR 
imaging has little role for determining extent of disease in male 
patients since the majority will be treated by mastectomy. 
 
Histopathology 
Most male breast cancers are invasive at presentation with only 
10% having ductal carcinoma in situ (DCIS) (Table 3) 
[29,32,33,36–38]. The majority are invasive ductal carcinomas 









Table 3: Histopathological types of male breast cancer 
 
 
(80%) with only 1% of male breast cancers being lobular in 
origin, since in the male breast, lobule development is 
dependant upon oestrogenic stimulation. 
Paget's disease and inflammatory breast cancer occur in similar 
proportions in men and women with breast cancer. Rarer 
histological subtypes, medullary, tubular, mucinous and 
squamous have all been reported. Non-invasive disease is 
usually DCIS of low or intermediate grade, but lobular 
carcinoma in situ (LCIS) has been described, usually coexisting 
with invasive lobular carcinoma [39]. 
Oestrogen receptors are expressed in 90% of MBCs, a higher 
proportion than in women and up to 96% are progesterone 
receptor positive [40,41]. Human epidermal growth factor 
receptor 2 (Her-2) overexpression has been reported in 16%, on 
average [40,42,43] slightly lower than in females but its effects 
on prognosis are unclear [44]. 
 
Management 
The principles of treatment of MBC are similar to those used for 
females with breast cancer. Men are less likely to have breast-
conserving surgery, radiotherapy or receive chemotherapy 
compared with stage-matched female cases [45]. Most breast 
units see few MBC patients each decade. Psychological support 
is very much orientated towards women, but psychological 
morbidity is also frequent amongst male patients who often 
have concerns about body image [46]. Additionally, MBC can be 
a very isolating diagnosis with some patients questioning their 
masculinity, and these concerns need to be addressed by those 
who are caring for the patient. 
Treatment of local disease 
Surgery 
Surgery is the mainstay of treatment for MBC and mastectomy 
is the most commonly performed operation because of the size 
of the male breast and most cancers being central with early 
nipple involvement. Radical mastectomy was the treatment of 
choice but this is now infrequently necessary [23]. Tumours 
close or attached to the pectoralis major can be excised with a 
small amount of muscle. 
Locally advanced tumours can be down staged with 
neoadjuvant therapy to enable mastectomy. For nonresponders, 
primary skin closure may not be possible after mastectomy so a 
latissimus dorsi or rectus sentinel node biopsy (SNB) is the 
standard of care in men and has the same sensitivity and 
specificity as that described in female patients [47]. When 
axillary nodes contain tumour, detected pre-operatively or after 
SNB a clearance should be performed. 
Endocrine therapy 
Since the majority of male breast cancers are oestrogen 
receptor positive (ER+ve), endocrine therapy is an integral part 
of treatment. Studies of tamoxifen in men, given for two years, 
have shown improvement in both disease free, and so the effect 
of this treatment in men may have been underestimated. 









Aromatase inhibitors have been used to treat advanced MBC 
but their adjuvant role has yet to be determined [29]. 
Radiotherapy 
The few small studies using radiotherapy in men show an 
improved local control but did not control for other prognostic 
variables [48,49]. MBC patients should be offered postoperative 
radiotherapy according to the guidelines drawn up for females. 
Those few men who have breast-conserving surgery should be 
offered post-operative radiotherapy. Men with large tumours, 
locally advanced disease, extensive axillary nodal involvement 
or poor prognostic factors such as high histological grade and 
vascular invasion should all be offered post-mastectomy 
radiotherapy. 
Chemotherapy 
Studies of adjuvant chemotherapy in MBC do show a benefit 
but again these were underpowered [50,51]. Adjuvant 
chemotherapy for MBC should be advised along the same 
principles as female patients although age and co-morbidity will 
render many unsuitable. 
 
Treatment of advanced disease 
Endocrine therapy is the usual treatment for metastatic MBC 
[52]. Orchidectomy has been used but selective oestrogen 
receptor modulator (SERM) therapy in the form of tamoxifen is 
now the treatment of choice. Aromatase inhibitors are not 
usually used as they only block peripheral oestrogen production 
that accounts for 80% of oestrogen production in men. There is 
a risk of aromatase inhibitors up-regulating testicular oestrogen 
production in those with an intact hypothalamic feedback loop. 
Those few men with ER–ve tumours can be treated with 
chemotherapy. Additionally, the use of androgens, anti-
androgens, steroids, oestrogens, progestins and 




Male and female patients with breast cancer are staged 
similarly, according to AJCC or UICC guidelines. Prognosis 
depends upon tumour size, histological grade, nodal status and 
hormone receptor status [53]. The most important prognostic 
factor is the lymph node status. Those who are node negative 
can expect a five-year survival rate of 90%, compared with 65% 
five-year survival rate for node positive cases. 
The number of involved nodes is also of prognostic significance: 
those with 1–3 positive nodes have a ten-year survival rate of 
44%, compared with 14% for patients with ≥ four nodes involved 
[54]. Histological tumour grade also plays a role: grade I 
patients have a five-year survival rate of 76%, dropping to 66% 
for those with grade II tumours and 43% for grade III cases. 
Patients with ER/PR+ve tumours fare better than those with 
ER/PR–ve disease. 
Overall, the prognosis is equivalent to that in stage-matched 
female patients. MBC patients tend to fare worse because of 
late presentation associated with more advanced disease. 
Because MBC cases tend to be older than female patients, 
there is an increased incidence of co-morbidities, which could 
adversely affect their prognosis [29]. 
 
Psycho-social aspects 
In females with breast cancer, clinically significant 
anxiety/depression occurs in up to 25% of cases [55,56,57]. 
Until recently, no structured psychosocial studies have been 
reported in MBC. In depth interviews of MBC patients indicated 
seven major areas of concern: delay in diagnosis, shock, 
stigma, body image, causal factors and lack of informational 
and emotional support [58]. Focus group discussions have 
suggested a particular need for gender-specific information on 
MBC together with provision of support [59]. 
In a national study, Brain et al administered questionnaires to 
161 MBC patients [60]. There was a low incidence of clinical 
levels of anxiety and depression, 6% and 1%, respectively, but 
23% stated that they had cancer-associated distress. These low 
levels of psychological morbidity may have related to the self-
selected nature of the participants. In a much smaller study, 
Donovan et al [61] reported four themes of experience for MBC 
patients, making sense of the diagnosis, challenge to 
masculinity, stigma of the diagnosis and the problems of 
interacting with health-care services. There is an evident need 
for national protocols for both information and support for men 
diagnosed with breast cancer. 
 
Acknowledgement 
Article was originally posted in the Breast Cancer Forum 
(http://www.breastcancer.org.uk). This forum is sponsored by an 
unrestricted grant from Sanofi-Aventis. 










1.  Joshi MG, Lee AK, Loda M et al (1996) Male breast 
carcinoma:an evaluation of prognostic factors 
contributing to a poorer outcome  Cancer  77  490–8 
PMID: 8630956  doi: 10.1002/(SICI)1097-0142(19960201) 
77:33.0.CO;2 
2.  O’ Malley CD, Prehn AW, Shema SJ et al (2002) 
Racial/ethnic differences in survival rates in a 
population based series of men with breast cancer 
Cancer 94  2836–42 PMID: 12115370  doi:  10.1002/cncr. 
10521 
3.  Hodgson NC, Button JH, Franceschi D et al (2004) Male 
breast cancer:is the incidence increasing?  Ann Surg 
Oncol  11  8 751–5 PMID: 15289238  doi: 10.1245/ASO. 
2004.01.001 
4.  El-Gazayerli MM and Abdel-Aziz AS (1963) On 
bilharziasis and male breast cancer in Egypt: a 
preliminary report and review of the literature  Br J 
Cancer 17 566–71 PMID: 14111594 
5.  Bhagwandin S (1972) Carcinoma of the male breast in 
Zambia East Afr Med J 49 176–9 
6.  Waterhouse J, Muir C, Correa P et al (1976) Cancer 
incidence in five continents vol 3 (Lyon: IARC Sci Publ) p 
15. 
7.  Anderson WF, Althuis MD, Brinton LA et al (2004) Is male 
breast cancer similar or different from female breast 
cancer? Br Cancer Res Treat 83 77–86 PMID 14997057 
doi:10.1023/B:BREA.0000010701.08825.2d 
8.  Basham VM, Lipscombe JM, Ward JM et al (2002) BRCA1 
and BRCA2 mutations in a population-based study of 
male breast cancer  Breast Cancer Res 4  1 R2 PMID: 
11879560 doi: 10.1186/bcr419 
9.  Friedman LS, Gayther SA, Kurosaki T et al (1997) 
Mutation analysis of BRCA1 and BRCA2 mutations in a 
male breast cancer population Am J Hum Genet 60 313–
9 PMID: 9012404 
10.  Fackenthal JD, Marsh DJ, Richardson AL et al (2001) Male 
breast cancer in Cowden syndrome patients with 
germline PTEN mutations J Med Genet 38 159–64 PMID: 
11238682 doi: 10.1136/jmg.38.3.159 
11.  Harnden DG, Maclean N and Langlands AO (1971) 
Carcinoma of the breast and Klinefelter’s syndrome J 
Med Genet 8  460 PMID: 4337761 doi: 10.1136/jmg.8.4. 
460 
12.  Price WH, Clayton JF, Wilson J, Collyer S and De Mey R 
(1985) Causes of death in X chromatin positive males 
(Klinefelter’s syndrome)  J Epidemiol Community Health 
39 330–6 PMID: 4086964 doi:  10.1136/jech.39.4.330 
13.  McLaughlin JK, Malker BR, Blot WJ et al (1988) 
Occupational risks for male breast cancer in Sweden Br 
J Indust Med 4 275–6 PMID 3378005 
14.  Hansen J (2000) Elevated risk for male breast cancer 
after exposure to gasoline and vehicular combustion 
products Am J Ind Med 37 349–52 PMID: 10706746 doi: 
10.1002/(SICI)1097-0274(200004)37:43.0.CO;2-L 
15.  Loomis DP (1992) Cancer of breast among men in 
electrical occupations  Lancet  339  1482–3  PMID: 
1351155 doi: 10.1016/0140-6736(92)92078-T 
16.  Lenfant-Pejovic M-H, Mlika-Cabanne N, Bouchardy C et al 
(1990) Risk factors for male breast cancer: a Franco-
Swiss case-control study Int J Cancer 45 661–5 PMID: 
2323842 doi: 10.1002/ijc.2910450415 
17.  Olsson H and Ranstam J (1988) Head trauma and 
exposure to Prolactin-elevating drugs as risk factors 
for male breast cancer  J Natl Cancer Inst 80  679–83 
PMID: 3373557 doi: 10.1093/jnci/80.9.679 
18.  Sasco AJ, Lowenfels AB and Pasker de Jong P (1993) 
Epidemiology of male breast cancer: a meta-analysis of 
published case-control studies and discussion of 
selected aetiological factors  Int J Cancer 53  539–49 
PMID 8436428 doi: 10.1002/ijc.2910530403 
19.  Dicker AP (2003) The safety and tolerability of low-dose 
irradiation for the management of gynaecomastia 
caused by antiandrogen monotherapy  Lancet Oncol 4 
30–6  PMID: 12517537  doi:  10.1016/S1470-2045(03) 
00958-6 
20.  Ron E, Ikeda T, Preston DL et al (2005) Male breast 
cancer incidence among atomic bomb survivors J Natl 
Cancer Inst 97  603–5  PMID: 15840883  doi:10.1093/jnci/ 
dji097 
21.  McClure JA and Higgins CC (1951) Bilateral carcinoma of 
male breast after estrogen therapy JAMA 146 7–9 
22.  Symmers WSC (1968) Carcinoma of the breast in trans-
sexual individuals after surgical and hormonal 
interference with the primary and secondary sexual 
characteristics  Br Med J 2 83–5 PMID: 5689553  doi:  
10.1136/bmj.2.5597.83 
23.  Thomas DB, Jimenez LM, McTiernan A et al (1992) Breast 
cancer in men: risk factors with hormonal implications 
Am J Epidemiol 135 734–48 PMID: 1350708 
24.  Thomas DB, Jimenez LM, McTiernan A et al (1992) Breast 
cancer in men: risk factors with hormonal implications 
Am J Epidemiol 135 734–48 PMID: 1350708 
25.  Johnson KC, Pan S Mao Y (2002) Risk factors for male 
breast cancer in Canada, 1994–1998 Eur J Cancer Prev 
11  253–63  PMID: 12131659  doi: 10.1097/00008469-
200206000-00009 









26.  Hsing AW, McLaughlin JK, Cocco P et al (1998)  Risk 
factors for male breast cancer (United States) Cancer 
Causes Control 9  269–76  PMID: 9684707  doi:  10.1023/ 
A:1008869003012 
27.  Guenel P, Cyr D, Sabroe S et al (2004) Alcohol drinking 
may increase the risk of breast cancer in men:a 
European population-based case-control study Cancer 
Causes Control 15 571–80 PMID: 15280636  doi: 10.1023/ 
B:CACO.0000036154.18162.43 
28.  Volm MD, Talamonti MS, Thangavelu M et al (1997) 
Pituitary adenoma and bilateral male breast cancer:an 
unusual association  J Surg Oncol 64 74–8 PMID: 
9040805  doi: 10.1002/(SICI)1096-9098(199701)64:13.0. 
CO;2-W 
29.  Fentiman IS, Fourquet A and Hortobagyi GN (2006) Male 
breast cancer Lancet 367 595–604 PMID: 16488803 doi:  
10.1016/S0140-6736(06)68226-3 
30.  Ribeiro GG, Swindell R, Harris M et al (1996) A review of 
the management of the male breast carcinoma based 
on an analysis of 420 treated cases Breast 5 141–6 doi: 
10.1016/S0960-9776(96)90058-2 
31.  van Geel AN, van Slooten EA, Mavrunac M et al (1985) A 
retrospective study of male breast cancer in Holland Br 
J Surg 72  724–7  PMID: 2994794  doi: 10.1002/bjs. 
1800720918 
32.  Goss PE, Reid C, Pintilie M et al (1999) Male breast 
carcinoma:a review of 229 cases who presented to the 
Princess Margaret Hospital during 40 years: 1955–1996 
Cancer  85 629–39 PMID: 10091736  doi:  10.1002/(SICI) 
1097-0142(19990201)85:33.0.CO;2-V 
33.  Scheike O (1975) Male breast cancer  Acta Pathol 
Microbiol Scand S251 3–35 PMID 1138536 
34.  Ramantanis G, Besbeas S, Garas JG et al (1980) Breast 
cancer in the male: a report of 138 cases World J Surg 4 
621–4 PMID: 7233931 doi: 10.1007/BF02401650 
35.  Stewart RAL, Howlett DC and Hearn FJ (1997) Pictorial 
review: the imaging features of male breast disease 
Clin Radiol 52 739–44 PMID: 9366531 doi: 10.1016/S0009-
9260(97)80151-1 
36.  Donegan WL, Redlich PN, Lang PJ and Gall MT (1998) 
Carcinoma of the breast in males Cancer 83  498–509 
PMID: 9690543  doi: 10.1002/(SICI)1097-0142(19980801) 
83:33.0.CO;2-R 
37.  Stalsberg H, Thomas DB, Rosenblatt KA et al (1993) 
Histologic types and hormone receptors in breast 
cancer in men: a population-based study in 282 United 
States men  Cancer Causes Control 4  143–51  PMID: 
8386948 doi: 10.1007/BF00053155 
38.  Giordano SH, Cohen DS, Buzdar AU et al (2004) Breast 
carcinoma in men: a population based study  Cancer 
101 51–7 PMID: 15221988 doi: 10.1002/cncr.20312 
39.  Michaels BM, Nunn CR and Roses DF (1994) Lobular 
carcinoma of the male breast Surgery 115 402–5 PMID: 
8128366 
40.  Rayson D, Erlichman C, Suman VJ et al (1998) Molecular 
markers in male breast carcinoma Cancer 83 2139–49 
PMID: 9827718  doi: 10.1002/(SICI)1097-0142(19981115) 
83:103.0.CO;2-F 
41.  Meijer-van Gelder ME, Look MP, Bolt-de Vries J et al 
(2001)  Clinical relevance of biologic factors in male 
breast cancer Breast Cancer Res Treat 68 249–60 PMID: 
11727961 doi: 10.1023/A:1012221921416 
42.  Wang-Rodriguez J, Cross K, Gallagher S et al (2002) Male 
breast cancer: correlation of ER, PR, Ki-67, HER2/neu 
and P53 with treatment and survival, a study of 65 
cases  Mod Pathol 15  853–61  PMID: 12181271  doi: 
10.1097/01.MP.0000022251.61944.1D 
43.  Dakin Haché K, Gray S, Barnes PJ et al (2007) Clinical 
and pathological correlations in male breast cancer: 
intratumoral aromatase expression via tissue 
microarrays Breast Cancer Res Treat 105 169–75 PMID: 
17268818 doi: 10.1007/s10549-006-9448-9 
44.  Bloom KJ, Govil H, Gattuso P et al (2001) Status of HER-2 
in male and female breast carcinomas  Am J Surg 82 
389–92  PMID: 11720677  doi: 10.1016/S0002-9610(01) 
00733-4 
45.  Scott-Connor CE, Jochimsen PR, Menck HR et al (1999) 
An analysis of male and female breast cancer 
treatment and survival among demographically 
identical pairs of patients  Surgery  126  775–80  PMID: 
10520928 doi:10.1016/S0039-6060(99)70135-2 
46.  France L, Michie S, Barrett-Lee P et al (2000) Male breast 
cancer: a qualitative study of male breast cancer Breast 
9 342–8 PMID: 14965759 doi: 10.1054/brst.2000.0173 
47.  Albo D, Ames FC, Hunt KK et al (2003) Evaluation of 
lymph node status in male breast cancer patients:a 
role for sentinel lymph node biopsy Breast Cancer Res 
Treat  77  9–14  PMID: 12602900  doi:    10.1023/A: 
1021173902253 
48.  Cutuli B, Lacroze M, Dilhuydy JM et al (1995) Male breast 
cancer:results of the treatments and prognostic factors 
in 397 cases Eur J Cancer 31A 1960–64 PMID: 8562148 
doi: 10.1016/0959-8049(95)00366-5 
49.  Erlichman C, Murphy KC and Elhakim T (1984) Male 
breast cancer: a 13 year review of 89 patients  J Clin 
Oncol 2 903–9 PMID: 6086848 









50.  Giordano SH, Perkins GH, Broglio K et al (2005) Adjuvant 
systemic therapy for male breast cancer  Cancer  104 
2359–64 PMID: 16270318 doi: 10.1002/cncr.21526 
51.  Yildirim E and Berberoglu U (1998) Male breast cancer: a 
22 year experience Eur J Surg Oncol 24 548–52 PMID: 
9870732 doi: 10.1016/S0748-7983(98)93608-3 
52.  Jaiyesimi IA, Buzdar AU, Sahin AA et al (1992) Carcinoma 
of the male breast  Ann Internal Med 117  771–7  PMID: 
1416579 
53.  Irvine T and Fentiman S (2007) Male breast cancer CML 
Breast Cancer 19 1 1–6 
54.  Guinee VF, Olsson H, Moller T, Shallenberger RC, van den 
Blink JW et al (1993) The prognosis of breast cancer in 
males. A report of 335 cases Cancer 71 1 154–61 PMID: 
8416712 doi: 10.1002/1097-0142(19930101)71:13.0.CO;2 
55.  Morris T, Goodyer HS and White P (1977) Psychological 
and social adjustment to mastectomy: a two year 
follow-up study  Cancer  40  2381–7  PMID: 922679  doi: 
10.1002/1097-0142(197711)40:53.0.CO;2-B 
56.  Maguire GP, Lee EG, Bevington DJ et al (1978) 
Psychiatric problems in the first year after mastectomy 
Br Med J 1 963–5 PMID: 565239 doi: 10.1136/bmj.1.6118. 
963 
57.  Dean C (1987) Psychiatric morbidity following 
mastectomy: preoperative predictors and types of 
illness J Psychosom Res 31 385–92 PMID: 3625592 doi: 
10.1016/0022-3999(87)90059-6 
58.  France L, Michie S, Barrett-Lee P et al (2000) Male breast 
cancer: a qualitative study of male breast cancer Breast 
9 342–8 PMID: 14965759 doi: 10.1054/brst.2000.0173 
59.  Williams BG, Iredale R, Brain K et al (2003) Experiences 
of men with breast cancer: an exploratory focus group 
study  Br J Cancer 89  1834–6  PMID: 14612888  doi: 
10.1038/sj.bjc.6601305 
60.  Brain K, Williams B, Iredale R et al (2006) Psychological 
distress in men with breast cancer J Clin Oncol 24 95–
101 PMID: 16382118 doi: 10.1200/JCO.2006.10.064 
61.  Donovan  et al  http://www.medscape.com/viewarticle/ 
566993 (accessed 15 November 2008) 
 8  www.ecancermedicalscience.com 
R
e
v
i
e
w
s